Key Dates

Related Announcements

RFA-DA-23-059: HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional)

NOT-HL-22-059: Notice of NHLBI Participation in RFA-DA-23-060 "HEAL Initiative - Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program: Leadership and Data Co-ordinating Center (U01 Clinical Trial Optional)"

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in RFA-DA-23-059 "HEAL Initiative: Sleep Predictors of Opioid-Use Disorder Treatment Outcomes Program (R01 Clinical Trial Optional)".

The following sections of RFA-DA-23-059 have been updated (in bold italics) to reflect NHLBI participation in this Funding Opportunity Announcement.

Part 1. Overview Information

Components of Participating Organizations

National Institute on Drug Abuse (NIDA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Center for Complementary and Integrative Health (NCCIH)

National Heart, Lung, and Blood Institute (NHLBI)

Catalog of Federal Domestic Assistance (CFDA) Number(s): 93.279, 93.213, 93.273, 93.838, 93.233

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)
Aaron D. Laposky, PhD
National Heart, Lung, Blood Institute (NHLBI)
Telephone: (301) 827-7837
Email: [email protected]

Grants Management Contact(s)
Nina Hall
Telephone: (301) 827-2393
Email: [email protected]

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries regarding this Notice to:

Scientific/Research Contact(s)
Aaron D. Laposky, PhD
National Heart, Lung, Blood Institute (NHLBI)
Telephone: (301) 827-7837
Email: [email protected]